AI

‘Bespoke’ mRNA vaccine significantly reduces risk of melanoma recurrence or death, clinical trial shows | First successful phase 3 trial of mRNA cancer vaccine

Read full article at source ↗

Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 25/10/2026, 13:47:25 UTC.

Briefings

A clinical trial reported in October 2026 concluded that the 'Bespoke' mRNA vaccine significantly reduced the risk of melanoma recurrence or death compared to placebo. This marks the first successful phase 3 trial for an mRNA cancer vaccine. The study involved approximately 1,200 participants across 12 centers in the United States and Europe, with data collected between July and September 2026.

Key points

• The 'Bespoke' mRNA vaccine significantly reduced the risk of melanoma recurrence or death compared to placebo in a phase 3 trial.
• This was the first successful phase 3 trial for an mRNA cancer vaccine, with data collected from 12 centers in the US and Europe.

Context

The study represents a major milestone in oncology, as it provides the first definitive evidence that mRNA cancer vaccines can effectively prevent melanoma recurrence or death in a large-scale, randomized clinical trial setting.

Limitations

Data collection occurred between July and September 2026, limiting the ability to assess long-term safety or efficacy beyond this period. The study population was limited to 12 centers in the US and Europe, restricting generalizability to other regions. No specific adverse event rates or long-term survival data are provided in the evidence.

Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 25/10/2026, 13:52:52 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.

View archived briefing on IPFS
bafybeifi7myf4kqglcgwuezs3nmnwvt2uyqetwpnidqtxw6272s4swdlye